UCB Annouces FDA Approval For Zilbrysq Autoinjector Self-Administration For Adults Living With Generalized Myasthenia Gravis

By Reuters News

- Ucb SA UCB.BR:

  • ANNOUNCES U.S. FDA APPROVAL FOR ZILBRYSQ (ZILUCOPLAN) AUTOINJECTOR SELF-ADMINISTRATION FOR ADULTS LIVING WITH GENERALIZED MYASTHENIA GRAVIS

  • PRIOR TO AUTOINJECTOR'S APPROVAL, ZILBRYSQ WAS AVAILABLE AS A SELF-ADMINISTERED PREFILLED SYRINGE (PFS)

  • EXPECTS AUTOINJECTOR TO BE AVAILABLE COMMERCIALLY IN Q1 2027

Source text: nPLX4555H6

Further company coverage: UCB.BR

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk